Let’s look at the key reasons that are pushing Acurx Pharmaceuticals Inc (ACXP) to new highs

On Friday, Acurx Pharmaceuticals Inc (NASDAQ: ACXP) was -5.83% drop from the session before settling in for the closing price of $0.33. A 52-week range for ACXP has been $0.30 – $2.39.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

During the last 5-year period, the sales drop of Healthcare Sector giant was -7.84%. When this article was written, the company’s average yearly earnings per share was at 42.53%. With a float of $26.71 million, this company’s outstanding shares have now reached $30.76 million.

Let’s determine the extent of company efficiency that accounts for 4 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.

Acurx Pharmaceuticals Inc (ACXP) Breakdown of a Key Holders of the stock

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Acurx Pharmaceuticals Inc stocks. The insider ownership of Acurx Pharmaceuticals Inc is 13.17%, while institutional ownership is 11.77%. The most recent insider transaction that took place on Jan 06 ’25, was worth 25,000. In this transaction Director of this company bought 24,631 shares at a rate of $1.01, taking the stock ownership to the 27,708 shares. Before that another transaction happened on Jan 06 ’25, when Company’s Director bought 24,631 for $1.01, making the entire transaction worth $25,000. This insider now owns 137,183 shares in total.

Acurx Pharmaceuticals Inc (ACXP) Recent Fiscal highlights

According to the Wall Street analysts, stocks earnings will be around 42.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.59% during the next five years compared to -7.84% drop over the previous five years of trading.

Acurx Pharmaceuticals Inc (NASDAQ: ACXP) Trading Performance Indicators

You can see what Acurx Pharmaceuticals Inc (ACXP) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.93.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.70, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.51 in one year’s time.

Technical Analysis of Acurx Pharmaceuticals Inc (ACXP)

Looking closely at Acurx Pharmaceuticals Inc (NASDAQ: ACXP), its last 5-days average volume was 1.29 million, which is a drop from its year-to-date volume of 2.91 million. As of the previous 9 days, the stock’s Stochastic %D was 12.01%.

During the past 100 days, Acurx Pharmaceuticals Inc’s (ACXP) raw stochastic average was set at 2.15%, which indicates a significant decrease from 7.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0501 in the past 14 days, which was higher than the 0.0412 volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $0.4378, while its 200-day Moving Average is $0.7652. However, in the short run, Acurx Pharmaceuticals Inc’s stock first resistance to watch stands at $0.3228. Second resistance stands at $0.3387. The third major resistance level sits at $0.3547. If the price goes on to break the first support level at $0.2909, it is likely to go to the next support level at $0.2749. Now, if the price goes above the second support level, the third support stands at $0.2590.

Acurx Pharmaceuticals Inc (NASDAQ: ACXP) Key Stats

There are 30,765K outstanding shares of the company, which has a market capitalization of 9.44 million. As of now, sales total 0 K while income totals -14,100 K. Its latest quarter income was 0 K while its last quarter net income were -2,150 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.